1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Earnings

'Positive' Signs Abound For Perrigo, But 'Uncertainty' From Pandemic Complicates Outlook

 
• By Malcolm Spicer

"With all the positive things, I'd normally be raising guidance right now," says CEO Murray Kessler as Perrigo reports first-quarter results. But manufacturing operations aren't normal, and neither is the consumer health product marketplace.

"Uncertainty Ahead” sign on a background of blue sky with clouds

Perrigo Co. PLC would have an outlook that couldn't be better if it wasn't for the uncertainty the COVID-19 pandemic imposes on manufacturing and the marketplace.

The OTC private label and store brand giant, with presence also in the infant formula, branded nutritional product and generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Trump’s Latest Tariff Order Reheats Consumer Worries And Price Increases In Healthcare Sector

 
• By Malcolm Spicer

When consumer health and beauty firms announce results for current quarter, they likely will note trend many reported after first quarter, an uptick in revenues and volume due to consumer concern about Trump’s tariffs gambit leading to higher product prices.

Moberg Has US Ambitions For Novel Nail Fungus Treatment

 
• By Tom Gallen

Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 
• By Malcolm Spicer

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By Tom Gallen

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

More from Business

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

 
• By Malcolm Spicer

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Complementary Medicine Move Paying Off For Galenica

 
• By Tom Gallen

Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.

Over The Counter: Turning Global Ambition Into Local Reality, With Haleon’s Jo Cooper

 
• By David Ridley

HBW Insight speaks to Haleon's UK & Ireland general manager Jo Cooper about how she plans to translate the firm's ambitious global growth strategy to a local context.